BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer

Phase 2negativeautogene cevumeranKeytrudaNegative

AI Analysis

Summary

BioNTech discontinued its Phase 2 trial of personalized mRNA vaccine autogene cevumeran in colorectal cancer due to futility, causing an 8% share decline. The setback comes as competitors Merck and Moderna recently achieved a Phase 3 win with their cancer vaccine plus Keytruda in melanoma.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Phase 2 trial discontinued for futility

Importance:7/10

Sentiment:

-0.80

mRNA vaccineoncologytrial discontinuationpersonalized medicinecompetitive landscape

Related Companies

$BNTX

Read the original article

Published by BioSpace on August 28, 2026 5:07 PM

Read Original